Perfusion Medical is commercializing a game-changing drug for the treatment of hemorrhagic shock and other ischemic conditions. The drug has been developed with more than $18 million in DoD funding and more than a dozen published studies from leading research institutions show the potential for the drug to help millions of patients.

Read More
Fixes capillary flow in
trauma and ischemia
Potential for 3x survival
Treats hemorrhagic shock,
AKI, Cardiac Shock & more

Latest News

View All
How it works graphic

How it works

The major mechanism of action of PEG-20k IV solution in treating severe hypovolemic shock is to increase tissue perfusion to facilitate rapid transfer of oxygen into oxygen starved tissues and organs. This is accomplished by reversing the metabolic cell and tissue swelling that occurs during shock, which causes no reflow by capillary compression.

Military Usage

The development of PEG-20k at VCU was funded with more than $10 million from the US Army. PEG-20k has tremendous potential to help war fighters and civilians